IL305314A - Genetically modified bacteria for generating vaccines - Google Patents

Genetically modified bacteria for generating vaccines

Info

Publication number
IL305314A
IL305314A IL305314A IL30531423A IL305314A IL 305314 A IL305314 A IL 305314A IL 305314 A IL305314 A IL 305314A IL 30531423 A IL30531423 A IL 30531423A IL 305314 A IL305314 A IL 305314A
Authority
IL
Israel
Prior art keywords
bacteria
cancer
vaccine
breast
actinobacteria
Prior art date
Application number
IL305314A
Other languages
English (en)
Hebrew (he)
Inventor
STRAUSSMAN Ravid
SANDLER Oded
RIFF Reut
Original Assignee
Yeda res & development co ltd
STRAUSSMAN Ravid
SANDLER Oded
RIFF Reut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda res & development co ltd, STRAUSSMAN Ravid, SANDLER Oded, RIFF Reut filed Critical Yeda res & development co ltd
Publication of IL305314A publication Critical patent/IL305314A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001162Kinases, e.g. Raf or Src
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL305314A 2021-02-18 2022-02-17 Genetically modified bacteria for generating vaccines IL305314A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150681P 2021-02-18 2021-02-18
PCT/IL2022/050191 WO2022175951A1 (en) 2021-02-18 2022-02-17 Genetically modified bacteria for generating vaccines

Publications (1)

Publication Number Publication Date
IL305314A true IL305314A (en) 2023-10-01

Family

ID=80623424

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305314A IL305314A (en) 2021-02-18 2022-02-17 Genetically modified bacteria for generating vaccines

Country Status (6)

Country Link
US (1) US20240009286A1 (https=)
EP (1) EP4294429A1 (https=)
JP (1) JP2024506954A (https=)
CA (1) CA3208536A1 (https=)
IL (1) IL305314A (https=)
WO (1) WO2022175951A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295726A (en) 2022-08-17 2024-03-01 Yeda res & development co ltd Genetically modified bacteria for generating vaccines
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor
WO2025177207A1 (en) * 2024-02-21 2025-08-28 Baccine Ltd Inducible immunomodulating tumor-homing bacteria

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1943344A2 (en) * 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
KR100985914B1 (ko) * 2006-12-13 2010-10-08 주식회사 바이오리더스 간암 특이 항원인 알파­페토단백질의 표면발현벡터 및 이에의해 형질전환된 미생물
EP2604682A1 (en) * 2011-12-12 2013-06-19 Universite Joseph Fourier - Grenoble 1 Attenuated and adapted strain of pseudomonas for delivering antigens
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
EP3406731A1 (en) 2017-05-22 2018-11-28 Commissariat à l'Energie Atomique et aux Energies Alternatives Metabolic labeling of bacterial teichoic acids cell wall
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用dnaワクチンを標的とするネオアンチゲン

Also Published As

Publication number Publication date
WO2022175951A1 (en) 2022-08-25
JP2024506954A (ja) 2024-02-15
EP4294429A1 (en) 2023-12-27
CA3208536A1 (en) 2022-08-25
US20240009286A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
US20240009286A1 (en) Genetically modified bacteria for generating vaccines
Cremonesi et al. Gut microbiota modulate T cell trafficking into human colorectal cancer
Overacre-Delgoffe et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer
Akiyama et al. Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients
François et al. The CD4+ T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells
CN103149366B (zh) 活化辅助t细胞的方法以及用于该方法的组合物
Li et al. Detection and significance of TregFoxP3+ and Th17 cells in peripheral blood of non-small cell lung cancer patients
US20230203594A1 (en) Methods of diagnosing cancer and predicting responsiveness to therapy
Cho et al. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells
US20260048107A1 (en) Genetically modified bacteria for generating vaccines
US20240009287A1 (en) Method of generating vaccines
CN116874581A (zh) 可激活患者抗肿瘤免疫反应的人肿瘤抗原及应用
Mocellin et al. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment
JP2025131713A (ja) Hpv免疫療法
Olin et al. Superior efficacy of tumor cell vaccines grown in physiologic oxygen
Meng et al. Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses
Wang et al. Follistatin‐like protein 1 contributes to dendritic cell and T‐lymphocyte activation in nasopharyngeal carcinoma patients by altering nuclear factor κb and Jun N‐terminal kinase expression
Liu et al. LYG1 exerts antitumor function through promoting the activation, proliferation, and function of CD4+ T cells
Urosevic et al. Expression of melanoma‐associated antigens in melanoma cell cultures
Afkhamipour et al. Potential gastric cancer immunotherapy: stimulating the immune system with Helicobacter pylori pIRES2-DsRed-express-ureF DNA vaccines
Chu et al. Combined immunization against TGF-β1 enhances HPV16 E7-specific vaccine-elicited antitumour immunity in mice with grafted TC-1 tumours
Cheng et al. Biological activity of cytotoxic dendritic cells cocultured with cytokine-induced killer cells and their effect on acute leukemia cells
Boehm et al. Intratumoral administration of mRNA-1273 vaccine delays melanoma growth in mice
IL275746B2 (en) Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
Cesare et al. Gut microbiota modulate T cell trafficking into human colorectal cancer